Drug Profile
Research programme: gene therapies - Astellas Gene Therapies
Alternative Names: AAV-CASQ2 gene therapy - Audentes; AT 307Latest Information Update: 08 Apr 2021
Price :
$50
*
At a glance
- Originator Audentes Therapeutics
- Developer Astellas Gene Therapies
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Ventricular tachycardia
Most Recent Events
- 01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
- 15 Jan 2020 Audentes Therapeutics has been acquired by Astellas Pharma
- 24 May 2019 Discontinued - Preclinical for Ventricular tachycardia in USA (Parenteral) (Audentes Therapeutics pipeline, May 2019)